Glenmark Specialty S.A. (Glenmark), a subsidiary of the globally renowned Glenmark Pharmaceuticals Ltd., has entered into an exclusive marketing and distribution agreement with BeiGene, a leading oncology company. This strategic collaboration aims to bring BeiGene’s innovative cancer treatments, Tislelizumab and Zanubrutinib, to patients across India.

Tislelizumab, an advanced anti-PD-1 monoclonal antibody, is approved by regulatory authorities such as the NMPA, EMA, and FDA for treating advanced or metastatic esophageal squamous cell carcinoma, among other cancers. Zanubrutinib, a BTK inhibitor, is recognized for its efficacy in treating certain hematological malignancies. These approvals underscore the promising efficacy and safety profiles of both medications.

Under the terms of this partnership, Glenmark will handle the local development, registration, and distribution of these oncology medicines, significantly enhancing their availability to Indian cancer patients. Alok Malik, President and Business Head – India Formulations at Glenmark Pharmaceuticals Ltd., expressed enthusiasm about the collaboration, highlighting Glenmark’s dedication to improving healthcare access in India. “The addition of Tislelizumab and Zanubrutinib to our oncology portfolio underscores our commitment to the cancer patient community and our mission to provide access to novel therapies across India,” said Malik.

Adam Roach, Vice President and Head of Asia-Pacific at BeiGene, echoed these sentiments, emphasizing the shared vision of both companies to enhance healthcare accessibility in Asia. “This partnership is a testament to our mission-driven approach to increasing access to comprehensive healthcare solutions, especially in countries like India, where the cancer burden is rising,” Roach stated.

India, now the world’s most populous country with over 1.43 billion people, faces a significant healthcare challenge with rising cancer rates. Recent data indicates that India ranks third globally in cancer cases, with projections estimating an increase to 2.08 million cases by 2040—a 57.5 percent rise from 2020. Currently, cancer claims approximately 900,000 lives annually in the country. The prevalence of blood cancer is particularly concerning, as India ranks third highest globally, with a diagnosis occurring every five minutes and resulting in an estimated 70,000 deaths each year.

Amid these challenges, Glenmark’s collaboration with BeiGene represents a crucial step toward providing affordable and effective cancer therapies. This partnership aims to serve as a beacon of hope for Indian patients battling cancer, offering innovative treatments that could significantly improve their quality of life.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!